Id |
Subject |
Object |
Predicate |
Lexical cue |
T56 |
0-121 |
Sentence |
denotes |
Table 1 Details of studies representing protein database structures of major targets in coronavirus and their structures |
T57 |
122-165 |
Sentence |
denotes |
PDB ID Details Inhibitor IC50 Reference |
T58 |
166-175 |
Sentence |
denotes |
N protein |
T59 |
176-255 |
Sentence |
denotes |
4KXJ Interaction between PJ34 and NTD of N protein of HCoV-OC43 PJ34 - [26] |
T60 |
256-292 |
Sentence |
denotes |
3V3P Structure not released [30] |
T61 |
293-363 |
Sentence |
denotes |
4LM7 Interactions of NTD of N protein of HCoV-OC43 with UMP - [26] |
T62 |
364-434 |
Sentence |
denotes |
4LI4 Interactions of NTD of N protein of HCoV-OC43 with AMP - [26] |
T63 |
435-443 |
Sentence |
denotes |
Protease |
T64 |
444-498 |
Sentence |
denotes |
4TWY 3CLPro of SARS-CoV with an inhibitor 3BL [27] |
T65 |
499-558 |
Sentence |
denotes |
4TWW 3CLPro of SARS-CoV with an inhibitor 41 63 µM [27] |
T66 |
559-620 |
Sentence |
denotes |
4WY3 3CLPro of SARS-CoV with an inhibitor 3X5 240 µM [27] |
T67 |
621-680 |
Sentence |
denotes |
4OVZ CoV PLPro complexed with inhibitor P85 490 nM [31] |
T68 |
681-745 |
Sentence |
denotes |
3MJ5 SARS-CoV PLPro complexed with inhibitor GRM 320 nM [32] |
T69 |
746-778 |
Sentence |
denotes |
2FE8 SARS-CoV PLPro - - [33] |
T70 |
779-894 |
Sentence |
denotes |
1UK4 SARS-CoV 3CLPro and its interactions with an inhibitor Substrate analog hexapeptidyl CMK inhibitor IC50 ca. |
T71 |
895-905 |
Sentence |
denotes |
2 mM [34] |
T72 |
906-978 |
Sentence |
denotes |
1UJ1, 1UK3, 1UK2 SARS-CoV M-pro, apo-enzyme at different pH - - [34] |
T73 |
979-1038 |
Sentence |
denotes |
3VB6 SARS-CoV 3CLPro in complex with C6Z C6Z 39 µM [35] |
T74 |
1039-1092 |
Sentence |
denotes |
3VB5 SARS-CoV 3CLPro with C4Z C4Z 1.3-4.6 µM [35] |
T75 |
1093-1129 |
Sentence |
denotes |
3TLO HCoV-NL63 3CLPro - - [3637] |
T76 |
1130-1210 |
Sentence |
denotes |
6LU7 Main protease of 2019-nCoV and its complex with N3 (inhibitor) - - [38] |
T77 |
1211-1224 |
Sentence |
denotes |
Spike protein |
T78 |
1225-1327 |
Sentence |
denotes |
5ZUV HR1 motif of HCoV-229E in complex with EK1 Modified OC43-HR2P peptide (EK1) 0.19-0.62 µM [39] |
T79 |
1328-1376 |
Sentence |
denotes |
5ZVM EK1 in complex with SARS HR1 motif [39] |
T80 |
1377-1416 |
Sentence |
denotes |
5X4S NTD of SARS-CoV S protein [40] |
T81 |
1417-1449 |
Sentence |
denotes |
5WRG SARS-CoV S protein [41] |
T82 |
1450-1513 |
Sentence |
denotes |
6Q05 MERS-CoV S structure in complex with Sialyl-Lewis [42] |
T83 |
1514-1578 |
Sentence |
denotes |
6ACG SARS-CoV S protein: ACE-2 (conformation 1) complex [43] |
T84 |
1579-1643 |
Sentence |
denotes |
6ACK SARS-CoV S protein: ACE-2 (conformation 3) complex [43] |
T85 |
1644-1713 |
Sentence |
denotes |
3SCI RBD of S protein interaction with ACE-2 [44] to be published |
T86 |
1714-2001 |
Sentence |
denotes |
NTD=N-terminal domain, CoV=Coronovirus, 3CLPro=3C-like protease, PLpro=Papain-like protease, MERS=Middle East respiratory syndrome, SARS=Severe acute respiratory syndrome, ACE-2=Angiotensin converting enzyme-2, RBD=Receptor-binding domain, nCoV=Novel coronavirus, S protein=Spike protein |